Format
Sort by

Send to

Choose Destination

Search results

Items: 8

1.

Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study.

Ting LS, Benoit-Biancamano MO, Bernard O, Riggs KW, Guillemette C, Ensom MH.

Pharmacotherapy. 2010 Nov;30(11):1097-108. doi: 10.1592/phco.30.11.1097.

PMID:
20973683
2.

A pharmacogenetics study of the human glucuronosyltransferase UGT1A4.

Benoit-Biancamano MO, Adam JP, Bernard O, Court MH, Leblanc MH, Caron P, Guillemette C.

Pharmacogenet Genomics. 2009 Dec;19(12):945-54. doi: 10.1097/FPC.0b013e3283331637.

PMID:
19890225
3.

The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers.

Lévesque E, Delage R, Benoit-Biancamano MO, Caron P, Bernard O, Couture F, Guillemette C.

Clin Pharmacol Ther. 2007 Mar;81(3):392-400.

PMID:
17339869
4.
5.

Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer.

Gagnon JF, Bernard O, Villeneuve L, Têtu B, Guillemette C.

Clin Cancer Res. 2006 Mar 15;12(6):1850-8.

6.

Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium.

Lépine J, Bernard O, Plante M, Têtu B, Pelletier G, Labrie F, Bélanger A, Guillemette C.

J Clin Endocrinol Metab. 2004 Oct;89(10):5222-32.

PMID:
15472229
7.

Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver.

Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, Greenblatt DJ, von Moltke LL, Perussed L, Guillemette C.

Pharmacogenetics. 2004 Aug;14(8):501-15.

PMID:
15284532
8.
Items per page

Supplemental Content

Loading ...
Support Center